Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan

NEW YORK, March 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), Amgen Inc. (NASDAQ: AMGN), and Allergan Inc. (NYSE: AGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Johnson & Johnson Analyst Notes 

On March 24, 2014, Johnson & Johnson reported that on March 21, 2014, Janssen R&D Ireland (Janssen) announced the receipt of a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), with recommendation for Marketing Authorization in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. According to Janssen, the CHMP opinion was based on positive consistent results from three pivotal Phase 3 studies in patients with genotype 1 HCV: QUEST-1 and QUEST-2 in treatment-naïve patients and PROMISE in patients who have relapsed after prior interferon-based treatment. Additionally, Janssen stated that a final decision on simeprevir by the European Commission is anticipated during Q2 2014. Brian Woodfall, Head of Development & Global Medical Affairs, Infectious Diseases/Vaccines, Janssen, stated, "The CHMP positive opinion for simeprevir brings us another step closer to delivering an innovative therapy for patients suffering from this devastating disease. Simeprevir offers a potentially new treatment option and therefore renewed hope to people living with HCV." The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.AnalystsReview.com/03282014/JNJ/report.pdf

--

Merck & Co. Inc. Analyst Notes 

On March 24, 2014, Merck & Co. Inc. (Merck) announced that the new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172 and MK-8742 are scheduled to be presented at the 49^th Annual Meeting of the European Association for the Study of the Liver (EASL) also known as The International Liver Congress™ 2014 on April 9, 2014, to April 13, 2014, in London, UK. Dr. Eliav Barr, Vice President, Infectious Disease, Merck Research Laboratories, stated, "These additional clinical data for MK-5172 and MK-8742 build upon the clinical evidence collected to date across a broad spectrum of patients with chronic HCV. Based on these data, we are pursuing a Phase 3 clinical program for these potentially important investigational medicines." The full analyst notes on Merck & Co. Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/MRK/report.pdf

--

Pfizer Inc. Analyst Notes 

On March 25, 2014, Pfizer Inc. (Pfizer) announced that the PROFILE 1014, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib), met its primary objective of significantly prolonging progression-free survival in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) against standard platinum-based chemotherapy regimens. According to the Company, PROFILE 1014 is the second positive global Phase 3 study that evaluated XALKORI against chemotherapy. Additionally, the Company stated that no unexpected safety issues were identified in the PROFILE 1014 study. Dr. Mace Rothenberg, Senior Vice President of Clinical Development and Medical Affairs and Chief Medical Officer of Pfizer Oncology, stated, "The results of the PROFILE 1014 study are important in that they demonstrate, for the first time, that XALKORI is superior to standard chemotherapy doublet regimens in prolonging survival without progression as first-line treatment for patients with ALK-positive advanced NSCLC. These findings build upon the data from the PROFILE 1007 randomized Phase 3 study in previously treated patients and collectively establish XALKORI as a standard of care in both the first and second-line setting for patients with ALK-positive advanced NSCLC." The full analyst notes on Pfizer Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/PFE/report.pdf

--

Amgen Inc. Analyst Notes 

On March 24, 2014, Amgen Inc. (Amgen) announced that it will present the pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145). According to the Company, the results from the five Phase 3 studies with evolocumab are scheduled to be presented in three Featured Clinical Research and two Late-Breaking Clinical Trial sessions from March 29, 2014 to March 31, 2014, at the American College of Cardiology's 63rd Annual Scientific Session (ACC. 14) in Washington, DC. Sean E. Harper, M.D. Executive Vice President of Research and Development at Amgen, stated, "We are eager to share the detailed findings from our Phase 3 cholesterol-lowering studies of evolocumab at ACC. The robust data from these studies in more than 4,000 patients form the basis of our global filing plan and we look forward to potentially providing a new treatment option to improve the lives of patients with high cholesterol, who have increased LDL-C levels despite existing therapies." The full analyst notes on Amgen Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/AMGN/report.pdf

--

Allergan Inc. Analyst Notes 

On March 25, 2014, Allergan Inc.'s (Allergan) stock went up by 0.15%, closing the day's session at $124.57. In the past three months, Allergan shares went up by 14.68%, compared to the Dow Jones Industrial Average Index which went up by 0.06% during the same period. The full analyst notes on Allergan Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03282014/AGN/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review